In persons with T1D, most of their b cells are selectively destroyed, and some may remain dedifferentiated (46). Exogenous insulin administration schemes often fail to maintain fine-tuned glycemic control, which may lead to frequent unwarned hypoglycemic/hyperglycemic episodes associated with side effects and death risk. Transplantation of whole solid pancreas or isolated islets from cadaveric donors constitutes valid options to achieve insulin independence and/or diminish glycemia fluctuations. Pancreas transplantation is considered invasive and is often associated with comorbidities (47). Therefore, transplantation of isolated islets is presented as an appealing therapeutic option for labile T1D patients. The accessibility of islet transplantation as a wider therapeutic intervention is very limited due to a shortage of cadaveric donors and the existence of few centers worldwide with adequate expertise (https://citregistry.org/home).
Efforts in clinical research have contributed significantly to improving islet transplantation, achieving exogenous insulin independence in 50% of patients after 5 years of multidonor infusions. The latter constitutes a success rate similar to that of organ pancreas transplantation (48). These patients manifested a reduced frequency of hypoglycemic events.
Preservation of islet viability during and after isolation remains challenging because of a significant loss of functionality during islet preinfusion due to both mechanical and oxidative stress as well as activation of apoptotic pathways (49, 50). Therefore, novel procedures toward maintenance of islet viability and normal functionality before and after infusion will improve islet transplantation outcomes to efficiently treat many more people with labile T1D. In this scenario, cotransplantation of stem cells together with isolated islets has been investigated as a putative translational option for T1D. MSCs have been noted because of their anti-inflammatory, angiogenic and immune-regulatory capacities as well as their source of nourishing factors for islets (28, 51-53). Cotransplantation of MSCs with islets improved their survival and function in experimental diabetic mice using syngeneic and allogeneic settings and in immune-deficient mice (21, 28, 54-56).
MSCs possess the capacity to repair or attenuate tissue destruction by paracrine secretions or cell-to-cell contacts modulating inflammatory and immune reactions (11, 57). MSCs possess the capacity to repair tissues or attenuate destructive processes by paracrine secretion of cytokines as well as other factors, some of which have already been identified, such as tumor necrosis factor-inducible gene 6 (TSG-6) and stanniocalcin-1 (STC-1), which are able to decrease both inflammation and immune responses (30, 58). Furthermore, MSCs cultured as spheroids increase the surface expression of CXCR4 and adhesion to endothelial cells (58). Based on these reports and taking into account that obtaining skin tissue from adult humans is safe and minimally invasive, we set out to evaluate whether adult human skin fibroblast-like cells after aggregation in culture could acquire the aforementioned characteristics and thus contribute to improving islet transplantation outcomes in diabetic mice.
We describe a culture procedure that confers fibroblast-like cells obtained from adult human skin properties that improve marginal mass allogeneic islet transplantation in experimental diabetic mice. These results highlighted that the beneficial effects of cotransplantation of SphCs with marginal mass allogeneic islets could be due to its influence on the facilitation of islet engraftment and, inderectly, in the attenuation of the host's alloimmune response. The observed overall increase in islet cell viability finally led to better glycemic control in diabetic transplanted mice.
Adult human skin fibroblast-like cells cultured for 72 h as hanging drops formed spheroids of ~500/700 µm in diameter and composed of more than 95% living cells, similar to what has been reported using bone marrow (30). These cells spontaneously aggregated under gravity when cultured in hanging drops without the addition of any specific growth factor. We believe that the phenomenon of aggregation facilitates cell-to-cell contacts that might aid in maintaining the stemness of SphCs, as has already been demonstrated using 3D culture of MSCs (59, 60).
Spontaneously migrating cells from spheroids, e.g., SphCs, expanded in adherent plastic and retained the capacity to differentiate after induction in adipocytes, osteocytes and chondrocytes, similar to conventional MSCs. SphCs gained the expression of several CDs distinctive of MSCs (i.e., CD29/CD73/CD90 and CD105) with very low or absolute lack of expression of CD11b, CD31, CD34, CD45 and CD34 surface molecules (39). Since we found no expression of HLA-DR molecules on the surface of SphCs, they may remain undetectable to allogeneic effector T-CD4+ lymphocytes, as already reported in other studies using different sources of cells (61). After several months of SphCs administration, they did not show proliferation, maldifferentiation, or teratoma formation in immunodeficient mice. These last characteristics position SphCs as a very safe alternative with potential therapeutic use.
SphCs have immunoregulatory properties similar to MSCs (62). Our studies offer new insights into the immunomodulatory capacities of SphCs, focusing on their ability to diminish T-CD4+ cell proliferation and biasing the cytokine profile of stimulated splenocytes toward an increase in the Th2/Th1 ratio in vitro. We have previously described potent immunomodulatory features of a unique human stem cell population called multilineage-differentiating stress-enduring (Muse) cells derived from adipose tissue (20). Muse cells and ShpCs have the ability to grow in suspension as spheroids. Therefore, aggregation of cells forming clusters might be a key driving force to make cells express cytokines and soluble factors such as TGF-b1 released by Muse cells as prominent mediators of their immunomodulatory actions (20).
In vitro downmodulation of splenocytes by SphCs was much more effective than their primary skin counterparts, which indicates that a single culture step as a spheroid is sufficient to acquire such properties. We observed that SphCs significantly diminished the secretion of classic proinflammatory cytokines (IFN-g, IL-2, IL-6 and TNF-a) while increasing IL-4 (a Th2-hallmark cytokine) by activated splenocytes. Comparably, it was reported that MSCs grown as spheroids showed anti-inflammatory capacity and converted macrophages to an M2 phenotype through the expression of TSG-6 or prostaglandin E2 (30, 63, 64).
CD73 has ecto-5'-nucleotidase activity, which may change extracellular media, influencing immune responses such as inducing immune tolerance and T lymphocyte differentiation and tilting the balance toward immune-suppressive microenvironments (65, 66). Skin fibroblast-like cells cultured as spheroids gained surface expression of CD73 (60% increase vs primary skin cells, approximately; Fig. 2B). Extensive nucleotidase activity on the surface of SphCs might increase nucleoside concentrations and ultimately inhibit the proliferation and activation of allogeneic effector T lymphocytes (67).
Antigen-specific T lymphocytes are involved in the autoimmune process that destroys b cells in T1D (68). The early stages of the disease mobilize inflammatory infiltration into the islets with accumulation of immune cells in and around the islets (insulitis) (69), all of which contribute to b cell dysfunction and destruction (70). Proinflammatory cytokines secreted by infiltrated immune cells, such as IL-1b, IFN-g and TNF-a, impair the function and viability of pancreatic b cells (71).
We found that SphC conditioned media promoted cell death inhibition (approximately 50%) in isolated islets when they were challenged by a mixture of proinflammatory cytokines in vitro. Studies have confirmed that growth factors secreted by MSCs, such as VEGF, EGF and HGF (72, 73), may conserve islet integrity, growth and functionality. However, the mechanisms by which these factors are protective for b cells under cytokine injury are still unclear. They might act through classic regulators of b cell proliferation, such as Akt and Erk (74). Whether SphCs conditioned media may influence cell proliferation and/or regeneration of b cells might require prolonged culture periods of islets. Likewise, we did not observe improvements in basal insulin secretion or glucose-stimulated insulin secretion in islets exposed to SphCs conditioned media.
Transplanted islets encounter a rapid attack mediated by allogeneic destructive reactions after infusion (75-77). For all allogeneic forms of transplantation, antigen-presenting cells (APCs) infiltrating the graft become fully matured by the action of locally released proinflammatory mediators, ischemia and necrotic cells. Matured APCs migrate to secondary lymphoid organs where they stimulate the proliferation of both alloreactive T and recipient T cells recognizing allogeneic MHCs and allopeptides, respectively. These two populations of T cells mount the allo-response against the islets. Thus, the need for lifelong treatment to avoid rejection of allogeneic islets is mandatory and involves difficult management (78). The addition of MSCs at the site of transplantation may help immune tolerance and protect islets, avoiding the administration of high doses of toxic immunosuppressive drugs. We found that cotransplantation of marginal mass allogeneic islets with SphCs improved glycemic control in STZ-induced diabetic mice. We speculate that the success of this procedure is due in part to the local release of pro-survival factors impacting directly on islets, along with creating a favorable anti-inflammatory microenvironment. Added to this last situation is the immune-regulatory activity exerted by SphCs that keep alloreative T lymphocytes under control. All these features are therefore believed to be relevant for the beneficial effects observed in this T1D mouse model (14). The fact that infusing marginal mass allogeneic islets together with SphCs improves glycemia in diabetic mice but does not reach normal glucose levels may be attributable to an insufficient number (104 cells) of administered SphCs. Similar experiments employing a mixture of MSCs and islet-derived single cells at a 1:1 ratio transplanted in a mouse model of T1D reached lasting normoglycemia (55). Considering an estimated ~1500 cells in an islet (150 m diameter) (79), we cotransplanted SphCs:Islet-cells at a 1:45 ratio. Future experiments, increasing the aforementioned ratio at least 10 times, could improve the results obtained.
As soluble factors secreted by SphC have a favorable impact on the survival and functionality of islets, we hypothesized that proteins secreted differently by cells after aggregation as spheroids could be responsible for the beneficial effects observed on β cell viability. Therefore, we set out to identify proteins/peptides secreted by them. Protein secretome studies revealed that several biological processes and intracellular pathways were differentially regulated between SphCs and skin fibroblast-like cell-conditioned media (Figure 7). Within these pathways, we identified proteins that could target processes associated with b cell cytoprotection together with modulating immune responses. SphCs regulated approximately 70% of the proteins identified in the secretome compared with skin fibroblast-like cells.
The top hits on the functions displayed by these proteins were related to extracellular matrix remodeling, modulation of apoptosis and cell differentiation. It has been reported that low levels of some matrix metalloproteases might lead to an increased activity of membrane-bound FASL. Consequently, one might expect augmented apoptotic capacity by FASL-expressed SphCs on effector T-cells without affecting the viability of Treg lymphocytes, both contributing to a significant increase in b cell viability and islet graft lifespan (80, 81). We found that inhibitors of metalloproteases were upregulated in the SphCs secretome and could, partially, contribute to the less aggressive proinflammatory microenvironment created when these cells were cocultured with murine splenocytes.
The protein 14-3-3ζ, also upregulated in the SphCs secretome, has been implicated in the inhibition of b cell apoptosis induced by different stimuli (82). Both Gremlin-1 and pentatraxin-3, which are abundant in the secretome of SphCs, have been related to growth and survival in response to inflammation and tissue damage (83-86). There is no knowledge about gremlin-1 in the context of b cell biology. In tubular epithelial cells, gremlin-1 increased TFG-b production through Smad activation, inducing a myofibroblast-like phenotype (87).
Taken together, these results highlight the underscored ability of SphC to create a favorable niche for allo-islet reception, preserving islet viability and functionality and reducing the need for immune-suppressive drugs.
The possibility of using conditioned media from SphCs or a combination of factors identified in the secretome study could provide the flexibility of an off-the-shelf product for wider clinical applications. These proteins could be prepared as supplements to include in the cultured media at the time of transplantation and simply comixed with islets for delivery without the need to encapsulate or chemically modify the islets. Further innovations in culture conditions to generate more efficient SphCs as adjuvants of islet engraftment will move the islet transplant field closer to insulin independence by providing islets with increased cytoprotection and overcoming the requirement of risky chemotherapy for immune suppression.